Vision 1 year after gene therapy for Leber's congenital amaurosis.
暂无分享,去创建一个
Alexander Sumaroka | A. J. Roman | W. Hauswirth | T. Aleman | S. Kaushal | A. Cideciyan | S. Schwartz | T. Conlon | S. Boye | B. Byrne | S. Jacobson | A. Sumaroka | Samuel G Jacobson | Tomas S Aleman | Artur V Cideciyan | Alejandro J Roman | Elizabeth A M Windsor | Sharon B Schwartz | William W Hauswirth | Barry J Byrne | Sanford L Boye | Shalesh Kaushal | Thomas J Conlon | E. A. Windsor
[1] J. Vander. Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis , 2009 .
[2] W. Hauswirth,et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. , 2008, Human gene therapy.
[3] Edwin M Stone,et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics , 2008, Proceedings of the National Academy of Sciences.
[4] Nick Tyler,et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. , 2008, The New England journal of medicine.
[5] R. Roepman,et al. Leber congenital amaurosis: Genes, proteins and disease mechanisms , 2008, Progress in Retinal and Eye Research.